For example, ABBV-221 (target EGFR), Navitoclax (target Bcl-2, Bcl-x and Bcl-w), Selumetinib (target Raf/MEK/ERK) and INK128 (target TORC1/2) are in phase 1 NSCLC clinical trials [148]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.